
Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Drugs In Development, 2022, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 50, 44, 8, 120, 49 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 14 and 8 molecules, respectively.
Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Drugs In Development, 2022, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 50, 44, 8, 120, 49 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 14 and 8 molecules, respectively.
Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
459 Pages
- Introduction
- Global Markets Direct Report Coverage
- Hepatitis B – Overview
- Hepatitis B – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hepatitis B – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hepatitis B – Companies Involved in Therapeutics Development
- Abhelix LLC
- Achelois Cell Therapy
- Ai-biopharma SAS
- AiCuris Anti-infective Cures AG
- Albireo Pharma Inc
- Aligos Therapeutics Inc
- AlloVir Inc
- AlphaMab Co Ltd
- Alphamab Oncology
- Altimmune Inc
- Ancora Biotech LLC
- Antios Therapeutics Inc
- APITBIO Co Ltd
- Apros Therapeutics Inc
- Arcturus Therapeutics Holdings Inc
- Ascendo Biotechnology Inc
- Ascentage Pharma Group International
- Ascletis Pharma Inc
- Assembly Biosciences Inc
- AstriVax NV
- Aucta Pharmaceuticals LLC
- Auro Vaccines LLC
- Avalia Immunotherapies Ltd
- Beam Therapeutics Inc
- Beijing Advaccine Biotechnology Company Ltd
- Beijing Junke Huayuan Pharmaceutical Technology Co Ltd
- Beijing Kawin Technology Share-Holding Co Ltd
- Beijing Minhai Biotechnology Co Ltd
- Benitec Biopharma Inc
- Biological E Ltd
- Biomics Biopharma Ltd
- BioNet-Asia Co Ltd
- Biotron Ltd
- Bluejay Therapeutics Inc
- Bolder Biotechnology Inc
- Bonac Corp
- Brandenburg Antiinfektiva GmbH
- Bukwang Pharmaceutical Co Ltd
- CaroGen Corp
- Casterbridge Pharmaceuticals Inc
- CHA Vaccine Institute Co Ltd
- Chengdu Hyperway Pharmaceutical Co Ltd
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chong Kun Dang Pharmaceutical Corporation
- Chongqing Jiachen Biotechnology Ltd
- Chongqing Zhifei Biological Products Co Ltd
- Cinkate Corp
- ClearB Therapeutics Inc
- CN Bio Innovations Ltd
- Cocrystal Pharma Inc
- Collaborations Pharmaceuticals Inc
- ConserV Bioscience Ltd
- Curigin Co Ltd
- CyTuVax BV
- DelSiTech Ltd
- Dicerna Pharmaceuticals Inc
- Dong-A ST Co Ltd
- Door Pharmaceuticals LLC
- Drug Farm Inc
- Emergex Vaccines Holding Ltd
- Enanta Pharmaceuticals Inc
- Enochian Biosciences Inc
- Enyo Pharma SA
- Escient Pharmaceuticals Inc
- Etna Biotech Srl
- Evotec SE
- Evrys Bio
- Exavir Therapeutics Inc
- Excision BioTherapeutics Inc
- F. Hoffmann-La Roche Ltd
- FortuneRock (China) Ltd
- Fresh Tracks Therapeutics Inc
- Fujian Cosunter Pharmaceutical Co Ltd
- GemVax & KAEL Co Ltd
- GeneCure Biotechnologies LLC
- GeneLancet Biosciences Inc
- GeneScience Pharmaceuticals Co Ltd
- GeoVax Labs Inc
- Gilead Sciences Inc
- Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd
- Globeimmune Inc
- GNI Group Ltd
- Golden Biotechnology Corp
- Grifols SA
- GSK plc
- Guangdong East Sunshine Pharmaceutical Co Ltd
- Guangxi Hebabiz Pharmaceutical Co Ltd
- Guangzhou Henovcom Bioscience Co Ltd
- Guangzhou Lupeng Pharmaceutical Co Ltd
- Guangzhou Yipinhong Pharmaceutical Co Ltd
- Hangzhou Metai Pharmaceutical Technology Co Ltd
- HEC Pharma Co Ltd
- Henan Genuine Biotech Co Ltd
- Hepagene Therapeutics Shanghai Inc
- Hepion Pharmaceuticals Inc
- Huahui Anjian (Beijing) Biotechnology Co Ltd
- ImmuneMed Inc
- Immunocore Limited
- Indaptus Therapeutics Inc
- Inovio Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- IRBM Science Park SpA
- ISA Pharmaceuticals BV
- ISR Immune System Regulation Holding AB
- Jeil Pharmaceutical Co Ltd
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- Jubilant Therapeutics Inc
- Kainos Medicine Inc
- Kyung Dong Co Ltd
- LG Chem Ltd
- Ligand Pharmaceuticals Inc
- Lion TCR Pte Ltd
- Max Biopharma Inc
- Maxwell Biosciences Inc
- Microbiotix Inc
- Nanjing Yuandasai Weixin Biomedical Co Ltd
- Novo Medi Sciences Pvt Ltd
- Nucorion Pharmaceuticals Inc
- OliX Pharmaceuticals Inc
- Oncolys BioPharma Inc
- Palisades Therapeutics
- Palo Alto pharmaceuticals Inc
- PeLeMed Co Ltd
- PharmaEssentia Corp
- Prazer Therapeutics
- Precigen Inc
- Precision Biosciences Inc
- Profarma
- Prosit Sole Biotechnology (Beijing) Co Ltd
- Protheragen Inc
- Qilu Pharmaceutical Co Ltd
- Regeneron Pharmaceuticals Inc
- Regulus Therapeutics Inc
- Replicor Inc
- Resonance Health Ltd
- REYON Pharmaceutical Co Ltd
- Rodos BioTarget GmbH
- Samjin Pharm Co Ltd
- SCG Cell Therapy Pte Ltd
- Sclnow Biotechnology Co Ltd
- SFA Therapeutics Inc
- Shanghai Ark Biopharmaceutical Co Ltd
- Shanghai Changsen Pharmaceutical Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai HEP Pharmaceutical Co Ltd
- Shanghai Jinwei Biotechnology Co Ltd
- Shanghai Zhimeng Biopharma Inc
- Shantha Biotechnics Pvt Ltd
- Shenzhen BinDeBio Ltd
- Shionogi & Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- Silverback Therapeutics Inc
- Sinovac Biotech Ltd
- Sirnaomics Ltd
- SL VaxiGen Inc
- SQZ Biotechnologies Co
- Staidson BioPharma Inc
- Statera Biopharma Inc
- Suzhou Ribo Life Sciences Co Ltd
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Svenska Vaccinfabriken Produktion AB
- Taiga Biotechnologies Inc
- TaiGen Biotechnology Co Ltd
- Takeda Pharmaceutical Co Ltd
- Tekmira Pharmaceuticals Corporation
- Tetranov International Inc
- Tevogen Bio Inc
- Theravectys SA
- ToolGen Inc
- Transgene SA
- UBI Pharma Inc
- Vaccitech Plc
- Vaxart Inc
- Vaxine Pty Ltd
- VBI Vaccines Inc
- Vir Biotechnology Inc
- Viravaxx AG
- Viriom Inc
- Virion Therapeutics LLC
- Virocovax
- ViroStatics SRL
- VLP Biotech Inc
- Xi'an Xintong Pharmaceutical Research Co Ltd
- Xi'An Yufan Biotechnology Co Ltd
- Yangshengtang Co Ltd
- Yisheng Biopharma Co Ltd
- Zelluna Immunotherapy AS
- Zhengda Tianqing Pharmaceutical Group Co Ltd
- Zhuhai Trinomab Biotechnology Co Ltd
- Hepatitis B – Drug Profiles
- (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus) (pentavalent) vaccine – Drug Profile
- (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine – Drug Profile
- (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile
- (ledipasvir + sofosbuvir) – Drug Profile
- (plasmodium falciparum + hepatitis B) vaccine – Drug Profile
- A-204 – Drug Profile
- A-2342 – Drug Profile
- AB-101 – Drug Profile
- AB-161 – Drug Profile
- AB-729 – Drug Profile
- AB-836 – Drug Profile
- Ab-MVP – Drug Profile
- ABI-4334 – Drug Profile
- ABIH-0104 – Drug Profile
- ABIH-2158 – Drug Profile
- ABIH-3733 – Drug Profile
- ADV-311 – Drug Profile
- AGX-1009 – Drug Profile
- AiB-001 – Drug Profile
- AIC-649 – Drug Profile
- AK-0706 – Drug Profile
- ALG-000111 – Drug Profile
- ALG-000122 – Drug Profile
- ALG-000184 – Drug Profile
- ALG-000286 – Drug Profile
- ALG-001024 – Drug Profile
- ALG-001075 – Drug Profile
- ALG-020755 – Drug Profile
- ALG-093453 – Drug Profile
- ALG-125097 – Drug Profile
- ALG-125755 – Drug Profile
- ALG-125819 – Drug Profile
- ALVR-107 – Drug Profile
- Anti-HBV x CD3 – Drug Profile
- Antisense RNAi Oligonucleotide for Hepatitis B – Drug Profile
- Antisense RNAi Oligonucleotides for Hepatitis B – Drug Profile
- antroquinonol – Drug Profile
- APBA-101 – Drug Profile
- APG-1387 – Drug Profile
- APR-002 – Drug Profile
- ARB-168786 – Drug Profile
- ARB-1820 – Drug Profile
- ARB-199 – Drug Profile
- ARB-880 – Drug Profile
- AS-3 – Drug Profile
- ASC-42 – Drug Profile
- ASD-253 – Drug Profile
- Aspidasept – Drug Profile
- ATI-1428 – Drug Profile
- ATI-1645 – Drug Profile
- ATI-2173 – Drug Profile
- AVA-2100 – Drug Profile
- azvudine – Drug Profile
- BB-103 – Drug Profile
- BBT-012 – Drug Profile
- bepirovirsen sodium – Drug Profile
- bersacapavir – Drug Profile
- Bi-specific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology – Drug Profile
- BIO-101 – Drug Profile
- Biological-162 – Drug Profile
- BJT-574 – Drug Profile
- BJT-778 – Drug Profile
- BNC-1701 – Drug Profile
- Capsid Inhibitor – Drug Profile
- CARG-201 – Drug Profile
- CB-06 – Drug Profile
- CB-07 – Drug Profile
- CB06-036 – Drug Profile
- Cellular Immunotherapy for Hepatitis B – Drug Profile
- cemiplimab – Drug Profile
- cetrelimab – Drug Profile
- chronic hepatitis B vaccine – Drug Profile
- Chronic Hepatitis B Virus – Drug Profile
- ciclopirox olamine – Drug Profile
- CKD-388 – Drug Profile
- CLB-3000 – Drug Profile
- CS-002 – Drug Profile
- CVIHBV-002 – Drug Profile
- DA-2803 – Drug Profile
- daplusiran – Drug Profile
- DCRRG-1 – Drug Profile
- Decoy-20 – Drug Profile
- DF-006 – Drug Profile
- Drug 2 for Hepatitis B – Drug Profile
- Drug for Hepatitis B – Drug Profile
- Drug to Inhibit cccDNA for HBV Infection. – Drug Profile
- Drugs for Hepatitis B – Drug Profile
- Drugs for Hepatitis B and Hepatitis C – Drug Profile
- Drugs for Hepatitis B Infection – Drug Profile
- Drugs for Viral Infections – Drug Profile
- Drugs to Inhibit Reverse Transcriptase for Acquired Immunodeficiency Syndrome and Hepatitis B – Drug Profile
- EBT-107 – Drug Profile
- EDP-514 – Drug Profile
- ENOBHB-01 – Drug Profile
- entecavir ER – Drug Profile
- entecavir LA – Drug Profile
- envafolimab – Drug Profile
- EP-547 – Drug Profile
- EV-200 – Drug Profile
- EVT-075 – Drug Profile
- EVT-895 – Drug Profile
- EYP-001 – Drug Profile
- F-351 – Drug Profile
- fasiglifam – Drug Profile
- Freethiadine – Drug Profile
- Gene Therapy for Hepatitis B – Drug Profile
- Gene Therapy for Hepatitis B Infections – Drug Profile
- Gene Therapy to Activate IL-2 for Hepatitis B Infections – Drug Profile
- Gene Therapy to Inhibit HBeAg and HBsAg for Hepatitis B – Drug Profile
- GIGA-2339 – Drug Profile
- GL-100 – Drug Profile
- GP-605 – Drug Profile
- GS-4774 – Drug Profile
- GS-6779 – Drug Profile
- GSK-3528869A – Drug Profile
- GSK-3965193 – Drug Profile
- GSTHG-121 – Drug Profile
- GSTHG-131 – Drug Profile
- GSTHG-141 – Drug Profile
- H-05 – Drug Profile
- HBAI-20 – Drug Profile
- HBC-34 – Drug Profile
- HBF-0259 – Drug Profile
- HBV – Drug Profile
- HBV/HDV Entry Inhibitor – Drug Profile
- HEC-121120 – Drug Profile
- hepatitis (bivalent) vaccine – Drug Profile
- hepatitis A + hepatitis B vaccine – Drug Profile
- Hepatitis B – Drug Profile
- hepatitis B vaccine – Drug Profile
- hepatitis B vaccine 1 – Drug Profile
- Hepatitis B Virus – Drug Profile
- hepatitis vaccine – Drug Profile
- Hepatitis-B (IV) – Drug Profile
- hepenofovir fumarate – Drug Profile
- HepTcell – Drug Profile
- HH-003 – Drug Profile
- HH-006 – Drug Profile
- HIKC-001 – Drug Profile
- HNC-280 – Drug Profile
- HPG-3466 – Drug Profile
- HPG-4892 – Drug Profile
- HPG-6189 – Drug Profile
- HRS-5091 – Drug Profile
- HRS-9950 – Drug Profile
- HS-10234 – Drug Profile
- IMCI-109V – Drug Profile
- IMM-005 – Drug Profile
- INO-1800 – Drug Profile
- Interferon-alpha Receptor Agonist – Drug Profile
- IONIS-HBVLRx – Drug Profile
- ISA-104 – Drug Profile
- ISR-50 – Drug Profile
- ISR-51 – Drug Profile
- JBI-1527 – Drug Profile
- JLP-1901 – Drug Profile
- JNJ-0440 – Drug Profile
- JNJ-0535 – Drug Profile
- JNJ-4964 – Drug Profile
- JNJ-64457744 – Drug Profile
- KD-1904 – Drug Profile
- KN-059 – Drug Profile
- KW-018 – Drug Profile
- KW-019 – Drug Profile
- KW-027 – Drug Profile
- KW-037 – Drug Profile
- KW-040 siRNA – Drug Profile
- LBVD – Drug Profile
- LP-128 – Drug Profile
- LR-20062 – Drug Profile
- LT-V11 – Drug Profile
- LUNAR-HBV – Drug Profile
- LW-231 – Drug Profile
- MBT-1316 – Drug Profile
- MBX-6035 – Drug Profile
- metacavir – Drug Profile
- Monoclonal Antibodies for Hepatitis B – Drug Profile
- Monoclonal Antibody to Inhibit SIGLEC3 for Hepatitis B Virus Infections – Drug Profile
- morphothiadin mesilate – Drug Profile
- MTS-001 – Drug Profile
- NUC-1010 – Drug Profile
- OBPAI-004 – Drug Profile
- OLX-703A – Drug Profile
- PA-1010 – Drug Profile
- PBGENE-HBV – Drug Profile
- PBHBV-215 – Drug Profile
- PD-1 Antagonist + ropeginterferon alfa-2b – Drug Profile
- peginterferon alfa-2a LA – Drug Profile
- Peptide for Genitourinary System and Sex Hormones, NAFLD, Neurodegenerative Diseases, Ophthalmology and Hepatitis B Viral Infections – Drug Profile
- PF-06 – Drug Profile
- pradefovir mesylate – Drug Profile
- PRGN-2013 – Drug Profile
- PRX-202 – Drug Profile
- PSP-001 – Drug Profile
- QL-007 – Drug Profile
- QL-0A6a – Drug Profile
- RBT-05 – Drug Profile
- redasemtide trifluoroacetate – Drug Profile
- rencofilstat – Drug Profile
- REP-2139 – Drug Profile
- REP-2165 – Drug Profile
- RG-6084 – Drug Profile
- RG-6346 – Drug Profile
- RG-7854 – Drug Profile
- RG-7907 – Drug Profile
- RNAi Gene Therapy for Hepatitis B and C – Drug Profile
- ropeginterferon alfa-2b LA – Drug Profile
- SBT-8230 – Drug Profile
- SCG-201 – Drug Profile
- SCG-211 – Drug Profile
- Sci-B-Vac – Drug Profile
- selgantolimod – Drug Profile
- serplulimab – Drug Profile
- SFA-001 – Drug Profile
- SFR-9213 – Drug Profile
- SFR-9216 – Drug Profile
- SJP-004 – Drug Profile
- SJP-006 – Drug Profile
- SLV-30 – Drug Profile
- Small Molecule 1 for Hepatitis B – Drug Profile
- Small Molecule 2 for Hepatitis B – Drug Profile
- Small Molecule for HBV – Drug Profile
- Small Molecule for Hepatitis B – Drug Profile
- Small Molecule to Agonize TLR7 for Hepatitis B – Drug Profile
- Small Molecule to Inhibit DNA Polymerase for Hepatitis B – Drug Profile
- Small Molecules for Hepatitis B – Drug Profile
- Small Molecules for Hepatitis B and Cytomegalovirus (HHV-5) Infections – Drug Profile
- Small Molecules for Hepatitis B Infection – Drug Profile
- Small Molecules for Hepatitis B Infection and Oncology – Drug Profile
- Small Molecules for Viral Infections – Drug Profile
- Small Molecules to Agonize STING Receptor for Hepatitis B – Drug Profile
- Small Molecules to Antagonize Glucocorticoid Receptor for Viral Infections – Drug Profile
- Small Molecules to Inhibit HBeAg and HBsAg for Hepatitis B – Drug Profile
- -Small Molecules to Inhibit HBsAg for Hepatitis B – Drug Profile
- Small Molecules to Inhibit Histone Deacetylase for Hepatitis B – Drug Profile
- Small Molecules to Inhibit NTCP for Infectious Diseases and Unspecified Metabolic Diseases – Drug Profile
- SR-016 – Drug Profile
- Stem Cell Therapy for Central Nervous System, Infectious Disease, Oncology, Cardiovascular, Genetic Disorders, Women's Health and Musculoskeletal Disorders – Drug Profile
- STP-155G – Drug Profile
- STSG-0002 – Drug Profile
- SVF-001 – Drug Profile
- Synthetic Peptide to Inhibit SLC10A1 for Hepatitis B, Type 2 Diabetes and Unspecified Disease – Drug Profile
- Synthetic Peptides for Hepatitis B and Hepatitis D Infections – Drug Profile
- TBX-3400 – Drug Profile
- tenofovir disoproxil fumarate – Drug Profile
- tertomotide – Drug Profile
- TG-1050 – Drug Profile
- TG-HBV – Drug Profile
- TherVacB – Drug Profile
- thymalfasin – Drug Profile
- TNM-022 – Drug Profile
- TNM-023 – Drug Profile
- TQA-3605 – Drug Profile
- TQA-3729 – Drug Profile
- TQA-3810 – Drug Profile
- troxacitabine – Drug Profile
- TVAX-008 – Drug Profile
- UB-551 – Drug Profile
- vanitaracin A – Drug Profile
- VBI-2601 – Drug Profile
- VIR-2218 – Drug Profile
- VIR-3434 – Drug Profile
- Viral Diseases – Drug Profile
- VM-2500 – Drug Profile
- VRCHB-01 – Drug Profile
- VRON-0200 – Drug Profile
- VTP-300 – Drug Profile
- VXX-001 – Drug Profile
- VXX-002 – Drug Profile
- XTYW-001 – Drug Profile
- XVIR-210 – Drug Profile
- Y-101 – Drug Profile
- YSHBV-001 – Drug Profile
- YSHBV-002 – Drug Profile
- ZG-170607 – Drug Profile
- ZMH-1505R – Drug Profile
- ZYF-0057 – Drug Profile
- ZYF-0272 – Drug Profile
- Hepatitis B – Dormant Projects
- Hepatitis B – Discontinued Products
- Hepatitis B – Product Development Milestones
- Featured News & Press Releases
- Sep 27, 2022: Ascletis announces dosing of the first patient in the phase IIb expansion cohort of ASC22 (Envafolimab) for chronic hepatitis B functional cure
- Sep 22, 2022: Vir Biotechnology announces first patient dosed in the phase 2 SOLSTICE trial evaluating VIR-3434 for the treatment of chronic hepatitis D Virus Infection
- Sep 22, 2022: Vir Biotechnology announces first patient dosed in the phase 2 SOLSTICE trial evaluating VIR-2218 for the treatment of chronic hepatitis D Virus Infection
- Sep 21, 2022: VBI Vaccines announces presentation of physician-initiated compassionate use data of its 3-antigen hepatitis B Vaccine at the 2022 International HBV Meeting
- Aug 30, 2022: Arbutus Biopharma announces issuance of a new key U.S. patent related to AB-729
- Jul 25, 2022: Aligos Therapeutics initiates 12-week dosing cohort in Phase 1b study evaluating its class II capsid assembly modulator, ALG-000184
- Jul 20, 2022: Arbutus Biopharma provides update on the phase 2A combination trial with AB-729 and a capsid inhibitor
- Jun 28, 2022: VBI Vaccines announces new long-term follow-up clinical data for its 3-antigen adult hepatitis B vaccine presented at EASL 2022
- Jun 27, 2022: Arbutus to present scientific posters on AB-836 at EASL International Liver Congress 2022
- Jun 27, 2022: Arbutus to present scientific posters at EASL International Liver Congress 2022
- Jun 27, 2022: Karolinska Development’s portfolio company Svenska Vaccinfabriken presents scientific advancements at international conference
- Jun 26, 2022: Enanta Pharmaceuticals announces data presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2022
- Jun 26, 2022: Vir Biotechnology announces abstract highlighting new Hepatitis B data on VIR-3434 accepted for presentation at the International Liver Congress 2022
- Jun 26, 2022: Vir Biotechnology announces multiple abstracts highlighting new Hepatitis B data on VIR-2218 accepted for presentation at the International Liver Congress 2022
- Jun 26, 2022: VBI Vaccines announces abstract accepted for oral presentation at EASL 2022
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Hepatitis B, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
- Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
- Table 8: Number of Products under Development by Companies, 2022 (Contd..6)
- Table 9: Number of Products under Development by Companies, 2022 (Contd..7)
- Table 10: Number of Products under Development by Companies, 2022 (Contd..8)
- Table 11: Number of Products under Development by Companies, 2022 (Contd..9)
- Table 12: Number of Products under Development by Universities/Institutes, 2022
- Table 13: Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 14: Products under Development by Companies, 2022
- Table 15: Products under Development by Companies, 2022 (Contd..1)
- Table 16: Products under Development by Companies, 2022 (Contd..2)
- Table 17: Products under Development by Companies, 2022 (Contd..3)
- Table 18: Products under Development by Companies, 2022 (Contd..4)
- Table 19: Products under Development by Companies, 2022 (Contd..5)
- Table 20: Products under Development by Companies, 2022 (Contd..6)
- Table 21: Products under Development by Companies, 2022 (Contd..7)
- Table 22: Products under Development by Companies, 2022 (Contd..8)
- Table 23: Products under Development by Companies, 2022 (Contd..9)
- Table 24: Products under Development by Companies, 2022 (Contd..10)
- Table 25: Products under Development by Companies, 2022 (Contd..11)
- Table 26: Products under Development by Companies, 2022 (Contd..12)
- Table 27: Products under Development by Companies, 2022 (Contd..13)
- Table 28: Products under Development by Companies, 2022 (Contd..14)
- Table 29: Products under Development by Companies, 2022 (Contd..15)
- Table 30: Products under Development by Companies, 2022 (Contd..16)
- Table 31: Products under Development by Universities/Institutes, 2022
- Table 32: Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 33: Number of Products by Stage and Target, 2022
- Table 34: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 35: Number of Products by Stage and Target, 2022 (Contd..2)
- Table 36: Number of Products by Stage and Mechanism of Action, 2022
- Table 37: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 38: Number of Products by Stage and Route of Administration, 2022
- Table 39: Number of Products by Stage and Molecule Type, 2022
- Table 40: Hepatitis B – Pipeline by Abhelix LLC, 2022
- Table 41: Hepatitis B – Pipeline by Achelois Cell Therapy, 2022
- Table 42: Hepatitis B – Pipeline by Ai-biopharma SAS, 2022
- Table 43: Hepatitis B – Pipeline by AiCuris Anti-infective Cures AG, 2022
- Table 44: Hepatitis B – Pipeline by Albireo Pharma Inc, 2022
- Table 45: Hepatitis B – Pipeline by Aligos Therapeutics Inc, 2022
- Table 46: Hepatitis B – Pipeline by AlloVir Inc, 2022
- Table 47: Hepatitis B – Pipeline by AlphaMab Co Ltd, 2022
- Table 48: Hepatitis B – Pipeline by Alphamab Oncology, 2022
- Table 49: Hepatitis B – Pipeline by Altimmune Inc, 2022
- Table 50: Hepatitis B – Pipeline by Ancora Biotech LLC, 2022
- Table 51: Hepatitis B – Pipeline by Antios Therapeutics Inc, 2022
- Table 52: Hepatitis B – Pipeline by APITBIO Co Ltd, 2022
- Table 53: Hepatitis B – Pipeline by Apros Therapeutics Inc, 2022
- Table 54: Hepatitis B – Pipeline by Arcturus Therapeutics Holdings Inc, 2022
- Table 55: Hepatitis B – Pipeline by Ascendo Biotechnology Inc, 2022
- Table 56: Hepatitis B – Pipeline by Ascentage Pharma Group International, 2022
- Table 57: Hepatitis B – Pipeline by Ascletis Pharma Inc, 2022
- Table 58: Hepatitis B – Pipeline by Assembly Biosciences Inc, 2022
- Table 59: Hepatitis B – Pipeline by AstriVax NV, 2022
- Table 60: Hepatitis B – Pipeline by Aucta Pharmaceuticals LLC, 2022
- Table 61: Hepatitis B – Pipeline by Auro Vaccines LLC, 2022
- Table 62: Hepatitis B – Pipeline by Avalia Immunotherapies Ltd, 2022
- Table 63: Hepatitis B – Pipeline by Beam Therapeutics Inc, 2022
- Table 64: Hepatitis B – Pipeline by Beijing Advaccine Biotechnology Company Ltd, 2022
- Table 65: Hepatitis B – Pipeline by Beijing Junke Huayuan Pharmaceutical Technology Co Ltd, 2022
- Table 66: Hepatitis B – Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, 2022
- Table 67: Hepatitis B – Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
- Table 68: Hepatitis B – Pipeline by Benitec Biopharma Inc, 2022
- Table 69: Hepatitis B – Pipeline by Biological E Ltd, 2022
- Table 70: Hepatitis B – Pipeline by Biomics Biopharma Ltd, 2022
- Table 71: Hepatitis B – Pipeline by BioNet-Asia Co Ltd, 2022
- Table 72: Hepatitis B – Pipeline by Biotron Ltd, 2022
- Table 73: Hepatitis B – Pipeline by Bluejay Therapeutics Inc, 2022
- Table 74: Hepatitis B – Pipeline by Bolder Biotechnology Inc, 2022
- Table 75: Hepatitis B – Pipeline by Bonac Corp, 2022
- Table 76: Hepatitis B – Pipeline by Brandenburg Antiinfektiva GmbH, 2022
- Table 77: Hepatitis B – Pipeline by Bukwang Pharmaceutical Co Ltd, 2022
- Table 78: Hepatitis B – Pipeline by CaroGen Corp, 2022
- Table 79: Hepatitis B – Pipeline by Casterbridge Pharmaceuticals Inc, 2022
- Table 80: Hepatitis B – Pipeline by CHA Vaccine Institute Co Ltd, 2022
- Table 81: Hepatitis B – Pipeline by Chengdu Hyperway Pharmaceutical Co Ltd, 2022
- Table 82: Hepatitis B – Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
- Table 83: Hepatitis B – Pipeline by Chong Kun Dang Pharmaceutical Corporation, 2022
- Table 84: Hepatitis B – Pipeline by Chongqing Jiachen Biotechnology Ltd, 2022
- Table 85: Hepatitis B – Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
- Table 86: Hepatitis B – Pipeline by Cinkate Corp, 2022
- Table 87: Hepatitis B – Pipeline by ClearB Therapeutics Inc, 2022
- Table 88: Hepatitis B – Pipeline by CN Bio Innovations Ltd, 2022
- Table 89: Hepatitis B – Pipeline by Cocrystal Pharma Inc, 2022
- Table 90: Hepatitis B – Pipeline by Collaborations Pharmaceuticals Inc, 2022
- Table 91: Hepatitis B – Pipeline by ConserV Bioscience Ltd, 2022
- Table 92: Hepatitis B – Pipeline by Curigin Co Ltd, 2022
- Table 93: Hepatitis B – Pipeline by CyTuVax BV, 2022
- Table 94: Hepatitis B – Pipeline by DelSiTech Ltd, 2022
- Table 95: Hepatitis B – Pipeline by Dicerna Pharmaceuticals Inc, 2022
- Table 96: Hepatitis B – Pipeline by Dong-A ST Co Ltd, 2022
- Table 97: Hepatitis B – Pipeline by Door Pharmaceuticals LLC, 2022
- Table 98: Hepatitis B – Pipeline by Drug Farm Inc, 2022
- Table 99: Hepatitis B – Pipeline by Emergex Vaccines Holding Ltd, 2022
- Table 100: Hepatitis B – Pipeline by Enanta Pharmaceuticals Inc, 2022
- Table 101: Hepatitis B – Pipeline by Enochian Biosciences Inc, 2022
- Table 102: Hepatitis B – Pipeline by Enyo Pharma SA, 2022
- Table 103: Hepatitis B – Pipeline by Escient Pharmaceuticals Inc, 2022
- Table 104: Hepatitis B – Pipeline by Etna Biotech Srl, 2022
- Table 105: Hepatitis B – Pipeline by Evotec SE, 2022
- Table 106: Hepatitis B – Pipeline by Evrys Bio, 2022
- Table 107: Hepatitis B – Pipeline by Exavir Therapeutics Inc, 2022
- Table 108: Hepatitis B – Pipeline by Excision BioTherapeutics Inc, 2022
- Table 109: Hepatitis B – Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Table 110: Hepatitis B – Pipeline by FortuneRock (China) Ltd, 2022
- Table 111: Hepatitis B – Pipeline by Fresh Tracks Therapeutics Inc, 2022
- Table 112: Hepatitis B – Pipeline by Fujian Cosunter Pharmaceutical Co Ltd, 2022
- Table 113: Hepatitis B – Pipeline by GemVax & KAEL Co Ltd, 2022
- Table 114: Hepatitis B – Pipeline by GeneCure Biotechnologies LLC, 2022
- Table 115: Hepatitis B – Pipeline by GeneLancet Biosciences Inc, 2022
- Table 116: Hepatitis B – Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
- Table 117: Hepatitis B – Pipeline by GeoVax Labs Inc, 2022
- Table 118: Hepatitis B – Pipeline by Gilead Sciences Inc, 2022
- Table 119: Hepatitis B – Pipeline by Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd, 2022
- Table 120: Hepatitis B – Pipeline by Globeimmune Inc, 2022
- Table 121: Hepatitis B – Pipeline by GNI Group Ltd, 2022
- Table 122: Hepatitis B – Pipeline by Golden Biotechnology Corp, 2022
- Table 123: Hepatitis B – Pipeline by Grifols SA, 2022
- Table 124: Hepatitis B – Pipeline by GSK plc, 2022
- Table 125: Hepatitis B – Pipeline by Guangdong East Sunshine Pharmaceutical Co Ltd, 2022
- Table 126: Hepatitis B – Pipeline by Guangxi Hebabiz Pharmaceutical Co Ltd, 2022
- Table 127: Hepatitis B – Pipeline by Guangzhou Henovcom Bioscience Co Ltd, 2022
- Table 128: Hepatitis B – Pipeline by Guangzhou Lupeng Pharmaceutical Co Ltd, 2022
- Table 129: Hepatitis B – Pipeline by Guangzhou Yipinhong Pharmaceutical Co Ltd, 2022
- Table 130: Hepatitis B – Pipeline by Hangzhou Metai Pharmaceutical Technology Co Ltd, 2022
- Table 131: Hepatitis B – Pipeline by HEC Pharma Co Ltd, 2022
- Table 132: Hepatitis B – Pipeline by Henan Genuine Biotech Co Ltd, 2022
- Table 133: Hepatitis B – Pipeline by Hepagene Therapeutics Shanghai Inc, 2022
- Table 134: Hepatitis B – Pipeline by Hepion Pharmaceuticals Inc, 2022
- Table 135: Hepatitis B – Pipeline by Huahui Anjian (Beijing) Biotechnology Co Ltd, 2022
- Table 136: Hepatitis B – Pipeline by ImmuneMed Inc, 2022
- Table 137: Hepatitis B – Pipeline by Immunocore Limited, 2022
- Table 138: Hepatitis B – Pipeline by Indaptus Therapeutics Inc, 2022
- Table 139: Hepatitis B – Pipeline by Inovio Pharmaceuticals Inc, 2022
- Table 140: Hepatitis B – Pipeline by Ionis Pharmaceuticals Inc, 2022
- Table 141: Hepatitis B – Pipeline by IRBM Science Park SpA, 2022
- Table 142: Hepatitis B – Pipeline by ISA Pharmaceuticals BV, 2022
- Table 143: Hepatitis B – Pipeline by ISR Immune System Regulation Holding AB, 2022
- Table 144: Hepatitis B – Pipeline by Jeil Pharmaceutical Co Ltd, 2022
- Table 145: Hepatitis B – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2022
- Table 146: Hepatitis B – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 147: Hepatitis B – Pipeline by Johnson & Johnson, 2022
- Table 148: Hepatitis B – Pipeline by Jubilant Therapeutics Inc, 2022
- Table 149: Hepatitis B – Pipeline by Kainos Medicine Inc, 2022
- Table 150: Hepatitis B – Pipeline by Kyung Dong Co Ltd, 2022
- Table 151: Hepatitis B – Pipeline by LG Chem Ltd, 2022
- Table 152: Hepatitis B – Pipeline by Ligand Pharmaceuticals Inc, 2022
- Table 153: Hepatitis B – Pipeline by Lion TCR Pte Ltd, 2022
- Table 154: Hepatit
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.